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Microglial cells are the resident immune cells of the central nervous system. In the resting
state, microglia are highly dynamic and control the environment by rapidly extending and
retracting motile processes. Microglia are closely associated with astrocytes and neurons,
particularly at the synapses, and more recent data indicate that neurotransmission plays
a role in regulating the morphology and function of surveying/resting microglia, as they
are endowed with receptors for most known neurotransmitters. In particular, microglia
express receptors for ATP and glutamate, which regulate microglial motility. After local
damage, the release of ATP induces microgliosis and activated microglial cells migrate
to the site of injury, proliferate, and phagocytose cells, and cellular compartments.
However, excessive activation of microglia could contribute to the progression of
chronic neurodegenerative diseases, though the underlying mechanisms are still unclear.
Microglia have the capacity to release a large number of substances that can be
detrimental to the surrounding neurons, including glutamate, ATP, and reactive oxygen
species. However, how altered neurotransmission following acute insults or chronic
neurodegenerative conditions modulates microglial functions is still poorly understood.
This review summarizes the relevant data regarding the role of neurotransmitter receptors
in microglial physiology and pathology.
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INTRODUCTION
Microglial cells constitute the resident immune cell population
of the mammalian central nervous system (CNS). Postnatally,
microglia are present in all regions of the CNS in a non-
overlapping territorial manner and comprise a large proportion
of the total cellularmakeup of the CNS, which is estimated to be as
high as 12% (Lawson et al., 1990). Similar to macrophages, their
peripheral counterparts, microglia display remarkable ranges of
morphology and activity depending, in part, on the state of the
surrounding tissue (Lynch, 2009; Ransohoff and Perry, 2009).
“Resting” microglia are not functionally silent cells, but extremely
dynamic in vivo, perpetually changing their morphology by
extending and retracting highly motile processes on a time scale
of minutes (Davalos et al., 2005; Nimmerjahn et al., 2005). In
response to local damage (few micron lesions), microglial pro-
cesses rapidly and automatically converge on the site of injury
without cell body movement. The microglial branching response
mediated by ATP release aims to shield and/or scavenge the
affected side. In addition, part of the dynamic motility of sur-
veying microglial processes in vivo is directed toward synapses,
suggesting that microglia vigilantly monitor and respond to the
functional status of synapses (Wake et al., 2009). In addition,
microglia have been reported to be capable of sensing defunct
synapses and phagocytose them in normal brain (Wake et al.,
2009; Tremblay et al., 2010). Synaptic pruning by microglia is
essential during development for the remodeling of synaptic cir-
cuits [Paolicelli et al., 2011; see also the reviews by Tremblay
(2011) and Wake et al. (2013)]. Microglia also efficiently phago-
cytose apoptotic neurons in the neurogenic niche (Sierra et al.,
2010).
In addition to its functions in normal brain, microglia are
involved in most, if not all, known CNS pathologies. More than
a decade ago, Georg Kreutzberg coined the term “microglial sen-
sor of pathology” (Kreutzberg, 1996), which captures the essence
of microglial cell function. Microglia are the brain’s intrinsic
immune cells and serve as damage sensors within the brain. Any
type of injury or pathological process leads to the activation
of these cells from their surveillant/resting state. In response to
injury, microglia change their highly branched and ramified mor-
phology by retracting their processes and taking on an ameboid
appearance. Activated microglial cells can then migrate to the site
of injury, proliferate, and release substances that affect patho-
logical processes. These substances include pro-inflammatory
cytokines, such as tumor necrosis factor (TNF)-α, and interleukin
(IL)-6 or IL-12, which signal the invading T lymphocytes.
Multiple signals converge on microglial cells to actively main-
tain or alter their functional state and orchestrate the specific
repertoire of microglial functions. Transitions between surveil-
lance and activated states are triggered when microglia per-
ceive a sudden appearance, abnormal concentration, or unusual
molecular format of certain factors (Hanisch and Kettenmann,
2007). This review focuses on the role of neurotransmitter recep-
tors, particular ATP and glutamate receptors, in the control
of microglial physiology and pathology. For the role of other
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receptors or channels, see these other excellent reviews (Pocock
and Kettenmann, 2007; Kettenmann et al., 2011).
ATP RECEPTORS
EXPRESSION OF ATP RECEPTORS IN MICROGLIA
Purines and pyrimidines act as widespread extracellular signaling
molecules. The physiological effects of purines and pyrimidines
are mediated through an extended family of purinoceptors acti-
vated by adenosine, classified as P1 receptors, or by ATP, clas-
sified as P2 receptors (Ralevic and Burnstock, 1998; North,
2002). Purinergic receptors are expressed in the majority of
living cells and are particularly abundant in glia (Pocock and
Kettenmann, 2007; Kettenmann et al., 2011). ATP activates a fam-
ily of metabotropic P2Y, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12,
P2Y13, P2Y14, and ionotropic P2X1-7 receptors. Extracellular
ATP is degraded to adenosine by ectonucleotidases, such as CD39
and CD73, which are known to be present in microglial cells
(Braun et al., 2000) and adenosine activates G protein-coupled
adenosine receptors A1, A2A, A2B, and A3. The A1 and A3 recep-
tors can inhibit adenylyl cyclase or activate phospholipase C,
whereas A2A and A2B receptors activate cyclic AMP produc-
tion (Fredholm et al., 2001). Collectively, the actions of ATP
and its degradation products produce responses that last from
milliseconds to minutes, and even longer time scales through
changes in gene regulation via second messengers (Khakh and
North, 2012). P2X receptors are non-selective cation channels
with high Ca2+ permeability that carry a depolarizing current
under standard physiological conditions. In some cells, P2X
channels are also significantly permeable to anions, such as the
full-length P2X5 receptor (P2X5R), which is permeable to Cl−
(North, 2002). Functional homomeric P2X1R and P2X3Rs have
fast desensitization properties. The other receptor types have
slow desensitization properties, except P2X7R, which does not
desensitize (Khakh and North, 2012). After prolonged activa-
tion, P2X7Rs open a large pore, causing cytolytic cell death
(Surprenant et al., 1996). Signaling diversity is increased by the
broad range of ATP sensitivities exhibited by ATP receptors, rang-
ing from nanomoles in the case of P2Y receptors to hundreds
of micromoles for P2X7Rs (North, 2002). Thus, ATP receptors
respond over remarkably broad spatiotemporal scales, making
ATP signaling highly dynamic.
P2X-mediated currents were identified in microglial cul-
tures prepared from human and rodent brains more than two
decades ago (Walz et al., 1993). Patch-clamp recordings have
shown that cultured microglial cells respond to extracellular ATP
(100μM) with the activation of a transient inward non-selective
cationic current, which is followed, in some cases, by an out-
ward K+ current (Walz et al., 1993; Nörenberg et al., 1994;
McLarnon et al., 1999). These results were recently corroborated
and extended in acute slices. Thus, ATP triggers a non-selective
cationic inward current in association with the activation of
P2X7Rs, and an outward K+ current associated with the acti-
vation of P2Y6 and P2Y12 metabotropic receptors (Boucsein
et al., 2003; Avignone et al., 2008). Importantly, these stud-
ies describe diverse electrophysiological properties for microglial
cell types, one subtype with a lower resting membrane poten-
tial (between −50mV and −60mV) and another subtype with
a higher membrane potential (−20 to −30mV), and on the basis
of different responses to ATP. These differences may be associated
with the different functional roles of microglia.
Immunohistochemical studies have shown the expression of
low levels of P2X4 (Ulmann et al., 2008) and P2X7 (Matute et al.,
2007) and high levels of P2Y12 (Haynes et al., 2006) in microglia
in the adult normal brain. The expression of purinergic receptors
changes during development (Xiang and Burnstock, 2005). Thus,
at embryonic day 16, the majority of microglial cells express P2X1
and P2X4 subunits, whereas only 30% of these cells express P2X7.
From postnatal day 7, P2X4-positive microglia locate preferen-
tially around blood vessels. At postnatal P30, the cells expressing
P2X1 virtually disappear, the P2X7-positive cells are distributed
widely through the forebrain, whereas cells bearing P2X4Rs are
mainly localized around blood vessels and lining the subarach-
noid space (Xiang and Burnstock, 2005). Constitutive expression
of P2X4 in pervivascular cells was also described in the adult
spinal cord (Guo and Schluesener, 2005). Pervivascular P2X4+
cells are ED1+/OX42+, indicating that correspond to infiltrating
monocytes/microglia, but not to lymphocytes.
From postnatal day 7, many microglial cells with P2X4
receptor-immunoreactivity were seen around the blood vessels.
At postnatal day 30, microglial cells with P2X1 receptor-
immunoreactivity disappeared and the cells with P2X4 receptor-
immunoreactivity were mainly localized around blood vessels
and lining the subarachnoid space. From postnatal day 30,
the microglial cells with P2X7 receptor-immunoreactivity were
found to be distributed widely in the forebrain. Cells with
P2X7 receptor-immunoreactivity from P30 were not labeled by
ED1, but some were labeled by isolectin B4. The expression of
P2X1, P2X4, and P2X7 receptor mRNA and protein on primary
cultures of rat microglial cells and on the N9 microglial cell
line was demonstrated with immunocytochemistry and RT-PCR.
This is the first report that the P2X1 receptor is expressed on
microglial cells, at least in early development, before postnatal
day 30.
Regarding adenosine receptors, in vitro functional studies have
identified the expression of all P1 adenosine receptors, A1, A2A,
A2B, and A3 receptors inmicroglia (Haskó et al., 2005; Abbracchio
and Ceruti, 2007). In vivo, the A2A receptor appears to be
expressed only in activated microglia after systemic lipopolysac-
charide (LPS) injection (Orr et al., 2009). In contrast, adult
healthy brains express relatively higher levels of A1 and A3 recep-
tors (Koizumi et al., 2013).
FUNCTIONS OF ATP RECEPTORS IN MICROGLIA
The initial microglial responses that occur after brain injury and
in various neurological diseases are characterized by microglial
accumulation in the affected sites of the brain as a result of the
migration and proliferation of these cells. The early-phase sig-
nal responsible for this accumulation is likely to be transduced
by rapidly diffusible factors, such as ATP. Purinergic receptors
control several microglial functions, including the motility of
their fine processes, migration, cytokine release, and phagocyto-
sis (Figure 1). LowATP concentrations almost exclusively activate
chemotaxis in order to recruit cells at the site of injury or
inflammation. When the ATP concentration increases, additional
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FIGURE 1 | Purinergic signaling in microglia. Release or leakage of
nucleotides/nucleosides from injured neurons, astrocytes, or microglial cells
induces phenotypic alterations in microglia. Microglial processes exhibit
constitutive motility, which is dependent on ATP signaling. Microglial
processes are rapidly recruited to sites of CNS tissue damage by P2Y12 and
A3 receptor activation. As the damage progresses, microglia undergo
progressive changes, including altered expression of cell surface markers and
inflammation-related genes, process retraction and the acquisition of an
ameboid morphology, cell body migration, and increasing phagocytic ability.
The changes in microglial functions are partly associated with changes in
purinergic receptors that determine different responses to ATP. Thus, process
retraction is mainly due to upregulation of A2A and downregulation of P2Y12
receptors, whereas migration is mediated by A1 and P2X4 receptors and
proliferation by P2X7 receptors. Phagocytosis signaling is also unmasked by
the upregulation of P2Y6, which is activated by the release of UTP by dying
cells. See also Table 1.
effector functions, such as phagocytosis and cytokine secretion,
are also triggered (Table 1).
Movement of the fine microglial processes is controlled pri-
marily through the activation of P2Y12 receptors, which are
expressed at high levels in microglia in normal brain. However,
P2Y12 receptors are downregulated in microglia after stroke or
activation by LPS (Haynes et al., 2006). Microglial chemotaxis is
characterized by cell body movement, as well as process move-
ment, and is mediated through the activation of P2X4 and P2Y12
receptors (Honda et al., 2001; Ohsawa et al., 2007). Haynes et al.
(2006) showed that, in P2Y12 receptor-null mice undergoing focal
laser cortical ablation, the chemotactic response of microglia was
markedly impaired in the first 40min of the observation period
compared to wild-type animals. However, when microglia from
mutant mice were examined 2 h after injury, the degree of chemo-
taxis approached that observed in wild-type animals. Moreover,
P2Y12 receptor expression on microglia was barely observable
24 h after injury. The loss of P2Y12 expression accompanied
microglial transformation from highly ramified to an amoe-
boid state. These observations indicate that P2Y12 receptors are
involved in the early, rather than late, responses of microglia to
injury (Haynes et al., 2006). In contrast, P2X4 has been shown to
be markedly upregulated after microglial activation; thus, chemo-
taxis after injury could be mediated by this receptor (Ohsawa
et al., 2007).
Phagocytosis is the terminal removal of cellular debris by
phagocytes. In vertebrates, phagocytosis is performed mostly by
macrophages and other specialized innate immune cells engulf-
ing the cellular debris in phagosomes, membrane protrusions
that fuse with lysosomes for terminal degradation. Although
phagocytosis is activated primarily by the expression of “eat-me”
signals on the surface of damaged or dead cells, injured neurons
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Table 1 | Expression and function of purinergic receptors on microglia.
Receptor type Presence Function References
P1
A1 + Migration/Neuropathic pain/Antiinflammatory properties Färber et al., 2008; Haselkorn et al., 2010; Luongo et al., 2012
A2A + Process retraction/Microglial activation Orr et al., 2009; Yao et al., 2012
A2B + Anti-inflammatory properties; release of IL-10 Koscsó et al., 2012
A3 + Process extension and migration Ohsawa et al., 2012
P2
Ionotropic
P2X1 − – Cavaliere et al., 2005; Xiang and Burnstock, 2005
P2X2 − – Unpublished observation
P2X3 + – Unpublished observaton
P2X4 + Migration/Neuropathic pain Ohsawa et al., 2007; Beggs et al., 2012
P2X5 ? –
P2X6 − – Cavaliere et al., 2005
P2X7 + Microglial proliferation/Inflammasome signaling Rigato et al., 2012; Volonte et al., 2012
Metabotropic
P2Y1 ? Purine release/Activation of a K+ current Boucsein et al., 2003; Ballerini et al., 2005
P2Y2 + Aβ(1–42) degradation and uptake Kim et al., 2012
P2Y4 + Not determined –
P2Y6 + Phagocytosis Koizumi et al., 2007
P2Y11 ? Microglial activation Brandenburg et al., 2010
P2Y12 + Process extension/Migration Haynes et al., 2006
P2Y13 + Neuropathic pain Kobayashi et al., 2012
P2Y14 + Neuropathic pain Kobayashi et al., 2012
?, Not determined
leak diffusible UDP signals that activate P2Y6-dependent phago-
cytic signaling in microglia (Koizumi et al., 2007). UDP, which
also acts on Gq-coupled P2Y6 receptors, induces the expression
of chemokines (Kim et al., 2011). In contrast to the positive
effect of P2Y6, the stimulation of P2X7 or P1 receptors atten-
uates microglial phagocytosis (Fang et al., 2009; Bulavina et al.,
2012). Phagocytosis by microglia is also regulated by the ratio of
P2/P1 activation. The interplay between P2 and P1 receptor acti-
vation is controlled by a cascade of extracellular enzymes that
dephosphorylate purines, resulting in the formation of adeno-
sine. In microglia, the capacity to degrade ATP and ADP depends
on the expression of ecto-nucleoside triphosphate diphosphohy-
drolase 1 (E-NTPDase1, also called CD39). Deletion of CD39
practically abolishes ATP degradation and increases microglial
phagocytic activity (Bulavina et al., 2012). Interestingly, the P2X7
receptor has also been detected in phagosomes. Lipids stimu-
late both actin assembly and the transport of ADP across the
phagosomal membrane into the lumen. In the lumen, ADP
is converted to ATP by adenylate kinase activity and activates
P2X7 receptors in phagosomes, triggering actin assembly on the
cytoplasmic membrane surface (Kuehnel et al., 2009a,b). These
data indicate a distinct role of intracellular P2X7 receptors in
phagocytosis.
In addition to its role in normal CNS function, ATP sig-
naling is involved in neuroinflammation in a broad range of
CNS pathologies (Di Virgilio et al., 2009). The extracellular
concentration of ATP increases dramatically during inflamma-
tion (Idzko et al., 2007; Pellegatti et al., 2008), and P2X7 receptors
are overexpressed in microglial cells in the neuroinflammatory
foci of numerous neurodegenerative conditions (Weisman et al.,
2012). The overexpression of P2X7 receptors in microglia, in the
absence of a pathological insult, is sufficient to drive the activation
and proliferation of microglia (Figure 1), which depends on the
pore-forming capacity of this receptor (Monif et al., 2009). The
activation of P2X7 receptors is coupled to the maturation and
secretion of the key pro-inflammatory cytokine IL-1β [Ferrari
et al., 1996; reviewed in Di Virgilio et al. (2009)], a signal-
ing pathway that depends on P2X7 coupling with pannexin-1
and subsequent casapse-1 activation (Pelegrin and Surprenant,
2006). Activation of the large-pore P2X7 receptor also leads to
the release of TNFα (Suzuki et al., 2004), the endocannabi-
noid 2-arachidonylglycerol (Witting et al., 2004), and superoxide
(Parvathenani et al., 2003). However, whether the pore capacity
of P2X7 depends on its coupling with pannexin-1 is a mat-
ter of debate. In neurons and astrocytes, pannexin1 appears to
be the molecular substrate for the permeabilization pore (or
death receptor channel) recruited into the P2X7 receptor sig-
naling complex (Locovei et al., 2007; Silverman et al., 2009).
In innate immune cells, including microglia and macrophages,
P2X7 signaling appears to be independent of pannexin-1 (Hanley
et al., 2012; Rigato et al., 2012). Thus, microglia proliferate and
phagocytose dying motor neurons during early embryonic spinal
cord invasion (Rigato et al., 2011). Notably, microglial invasion
and proliferation are controlled by P2X7 receptor signaling in a
pannexin-1-independent manner (Rigato et al., 2012). The pore
dilation capacity of P2X7 receptors in microglia does not depend
on the expression of pannexin-1 at this embryonic stage (Rigato
et al., 2012).
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The main function of adenosine receptors is the control of
innate immune function. Adenosine receptors A1 and A3 block
TNFα release by microglia, whereas A2B stimulates the produc-
tion and secretion of anti-inflammatory cytokine IL-10 (Koscsó
et al., 2012), indicating an anti-inflammatory role of P1 recep-
tor activation in the brain. Signaling through adenosine receptor
A2A drives the proliferation of spinal microglia after nerve injury
(Bura et al., 2008), and intrathecal blockade of this receptor
has been shown to abolish neuropathic pain in the same model
(Loram et al., 2009). Finally, adenosine can suppress inflamma-
tion and aid in tissue restitution, in part, by promoting alter-
native macrophage activation. Alternative activation occurs in
a Th2 cytokine environment and promotes the immunomod-
ulatory and anti-inflammatory, rather than pro-inflammatory,
properties of macrophages/microglia. Adenosine treatment of IL-
4- or IL-13-activated macrophages augments the expression of
alternative macrophage markers, primarily through the activa-
tion of A2B receptors, though A2A receptors also contribute to
the effect (Csóka et al., 2012). Acting through A3 receptors,
adenosine is also involved in the extension and migration of
microglial processes (Ohsawa et al., 2012). Interestingly, simul-
taneous stimulation of P2Y12 and A3 receptors is required for
microglial process extension, suggesting that intimate crosstalk
occurs between P2Y12 and A3 receptors.
CHANGES IN ATP RECEPTOR EXPRESSION IN MICROGLIA
Microglia adopt an appropriate stimulus modality–dependent
phenotype in response to injury or disease. The phenotypic
catalog of microglia includes proliferative, migrational, and
phagocytic responses, though how distinct the discrete molec-
ular fingerprints of the phenotypes are is not clear (Hanisch
and Kettenmann, 2007). Microglia undergo dramatic changes
in shape and gene expression patterns within hours of in vivo
activation, including modulation of the expression and function
of purinergic receptors (Figure 1). Remodeling of purinocep-
tor expression has been observed in situ in various pathological
models. Thus, epileptic seizures induced by kainate injections
trigger an activation of microglia in hippocampal slices (Avignone
et al., 2008), accompanied by an upregulation of the expression of
mRNA specific for P2X1, P2X4, P2X7, P2Y6, P2Y12, and P2Y13
receptors. Functionally, this upregulation manifests as an increase
in ATP-induced membrane currents and ATP-induced microglial
motility (Avignone et al., 2008). Depending on the microglial
stage, changes in purinergic expression determine the responses,
sometimes with opposite effects, to extracellular purines. For
example, the microglial chemotactic response to ATP is reversed
following microglial activation. The switch from process attrac-
tion to repulsion is driven by upregulation of the Gs-coupled A2A
receptor (Orr et al., 2009) concomitant with downregulation of
the Gi-coupled P2Y12 receptor (Haynes et al., 2006).
The extended and divergent time course of microglial activa-
tion suggests that the activation process is regulated by complex
mechanisms, which may differ significantly depending on the ini-
tiating stimulus. In vivo, P2Y12 receptor expression decreases as
microglia become activated after LPS injection in the striatum
(Haynes et al., 2006). In contrast, facial-nerve axotomy, a clas-
sical model of microglial activation, induces an upregulation of
microglial P2Y12 mRNA (Sasaki et al., 2003). Other stimuli, such
as epileptic seizures or trauma, also lead to rapid upregulation
of P2Y12 mRNA and protein in microglia (Franke et al., 2007;
Avignone et al., 2008; Tozaki-Saitoh et al., 2008).
The P2X4R has been reported to be associated with the acti-
vation of microglia/macrophages after CNS injury and may play
roles in inflammatory cascades involved in secondary brain dam-
age. The development of mechanical allodynia temporally corre-
lates with an increase in spinal P2X4R expression in microglia
(Ulmann et al., 2008). Microglial P2X4R upregulation, the
P2X4R+ state of microglia, seems to be common in most acute
and chronic neurodegenerative diseases associated with inflam-
mation. Microglial activation after traumatic brain injury also
parallels a significant increase in P2X4R expression in microglia,
which is suppressed by systemic treatment with dexamethasone
(Zhang et al., 2007). The upregulation of microglial P2X4Rs
has also been observed in animals expressing superoxide dismu-
tase 1 mutant, an animal model of amyotrophic lateral sclerosis
(D’Ambrosi et al., 2009), in the acute experimental autoimmune
encephalomyelitis (EAE) model of multiple sclerosis (MS) (Guo
and Schluesener, 2005), after spinal cord injury (Schwab et al.,
2005), and in cerebral ischemia (Cavaliere et al., 2003). Different
regulators of P2X4R expression in microglia have been described,
such as the chemokine CCL2 (also known as monocyte chemoat-
tractant protein, MCP-1; Biber et al., 2011; Toyomitsu et al.,
2012), interferon-γ (Tsuda et al., 2009), and the extracellular
matrix molecule fibronectin acting through Lyn kinase (Tsuda
et al., 2008, 2009).
The role of P2X4R in microglial activation and how its expres-
sion affects microglial functions is unclear. In neurons, P2X4R
influences inflammasome activation after spinal cord injury (de
Rivero Vaccari et al., 2012). The inflammasome is a multiprotein
complex that promotes the activation of caspase-1 and release of
mature inflammatory cytokines, such as IL-1β and IL-18. This
complex likely controls many aspects of neuroinflammatory pro-
cesses. P2X4 knock-out mice exhibit impaired inflammasome
signaling in the spinal cord, resulting in decreased IL-1β levels
and reduced infiltration of neutrophils andmonocyte-derivedM1
macrophages, resulting in significant tissue sparing and improved
functional outcomes (de Rivero Vaccari et al., 2012).
The metabotropic P2Y6R that controls microglial phagocyto-
sis is highly expressed in surveying microglia, but it is also slightly
upregulated in microglia following neuronal damage induced by
kainic acid injection in the hippocampus (Koizumi et al., 2007),
by trauma (Franke et al., 2007), or in animals expressing dismu-
tase 1 mutant (D’Ambrosi et al., 2009). These data point to a role
of this receptor in controlling the phagocytosis of necrotic cells
after damage (Koizumi et al., 2007). In contrast, the phagocytosis
of apoptotic cells prevents the spillover of cellular contents. Thus,
whether UDP levels are sufficient to activate the phagocytosis of
apoptotic cells or debris by microglia under normal physiological
conditions remains to be determined.
Finally, the expression of adenosine receptors varies depending
on microglial activation. Thus, surveying microglia express high
levels of A1 and A3 receptors, and activation leads to their down-
regulation. In contrast, the expression level of the adenosine A2A
receptor in surveying/resting microglia is relatively low, but LPS
Frontiers in Cellular Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 49 | 5
Domercq et al. Neurotransmitter receptors in microglia
dramatically increases its expression (Orr et al., 2009). The upreg-
ulation of A2A receptor expression is also observed in pathological
states, such as Parkinson disease and ischemia (Pedata et al., 2001;
Schwarzschild et al., 2006).
GLUTAMATE RECEPTORS
EXPRESSION OF GLUTAMATE RECEPTORS IN MICROGLIA
Glutamate is the major excitatory neurotransmitter of the CNS
and perturbations in this transmitter’s homeostasis have been
reported in most neurodegenerative diseases. Glutamate acti-
vates both ionotropic and metabotropic receptors. Ionotropic
receptors are classified into a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA), kainate, and N-methyl-d-
aspartate (NMDA) subtypes according to their preferred agonist.
Molecular cloning has revealed that each receptor subtype is
composed of several subunits with high homology within each
receptor class. Thus, AMPA receptors are formed by GluR1-4,
kainate receptors by GluR5-7 and KA1-2, and NMDA receptors
by NMDAR1, NMDAR2A-D, and NMDAR3A-B subunits (Cull-
Candy and Leszkiewicz, 2004). AMPA receptors are activated
by AMPA and kainate, whereas kainate receptors are activated
by kainate and are best functionally isolated in the presence
of GYKI53655, a selective AMPA receptor antagonist (Lerma,
2003). Similarly, metabotropic GluRs (mGluRs) can be classified
as group I (mGluR1, mGluR5), group II (mGluR2,mGluR3), and
group III (mGluR4, mGluR6-8) seven transmembrane receptors
(Swanson et al., 2005). The individual mGluR groups are cou-
pled to various G-proteins that activating phospholipase C (PLC,
group I) or inhibit adenylate cyclase (groups II and III).
Few studies have characterized the functional expression of
ionotropic glutamate receptors in microglial cells. An early study
showed inward currents corresponding to the activation of low-
Ca2+ permeability AMPA-type glutamate receptors (expressing
the GluR2 subunit) in cultured microglia, the activation of which
leads to TNF-α release [Noda et al., 2000; reviewed by Pocock and
Kettenmann (2007)]. AMPA-type glutamate receptor activation
also leads to c-fos expression (Eun et al., 2004). In contrast, no
direct evidence has been found for the functional expression of
kainate receptors in microglial cells. In contrast to in vitro condi-
tions, electrophysiological recordings of microglial cells in retina
or hippocampus slices clamped at −50mV failed to detect any
inward or outward current in response to glutamate or AMPA
(Wu and Zhuo, 2008; Fontainhas et al., 2011). The expression
of functional NMDA receptors in microglia in normal brain has
not been reported, but the activation of microglia after the induc-
tion of transient forebrain ischemia leads to NMDAR1 subunit
upregulation (Gottlieb and Matute, 1997). The functional sig-
nificance of NMDA receptor upregulation in microglia is still
unknown. However, NMDA injection into the somatosensory
cortex of newborn rats triggers transient microglial activation
(Acarin et al., 1996), whereas systemic administration of MK-801
prevents rapid microglial activation in the hippocampus, sec-
ondary to ischemic insults (Streit et al., 1992) or LPS treatment
(Thomas and Kuhn, 2005). Whether NMDA receptor activation
controls microglial activation directly or indirectly remains to be
determined. Therefore, additional studies are necessary to charac-
terize the existence of functional ionotropic glutamate receptors
in the resident and activated microglia of slices, which could
respond to glutamate release during synaptic activity or damage.
Regarding metabotropic glutamate receptors, different sub-
units of metabotropic groups I (mGluR5), II (mGluR2 and 3),
and III (mGluR4, 6, and 8, but not mGluR7) are expressed
by microglia and regulate microglial transformation into neu-
roprotective (via group III mGluRs) or neurotoxic (via group
II mGluRs) phenotypes (Biber et al., 1999; Taylor et al., 2002,
2003, 2005; Pocock and Kettenmann, 2007). Microglial activa-
tion of group II mGluRs, particularly mGluR2, induces TNF-α
and Fas ligand release, which trigger neuronal caspase-3 activa-
tion via TNFR1 (also known as p55) and Fas receptor, leading
to neuronal death (Taylor et al., 2005). However, an agonist of
mGluR3, a member of group II, has been shown to inhibit the
toxicity of microglia toward oligodendrocytes (Pinteaux-Jones
et al., 2008). Activation of groups II and III metabotropic glu-
tamate receptors also modulates LPS-induced glutamate release
by the xCT antiporter in microglia (McMullan et al., 2012), sug-
gesting a neuroprotective role of its activation. Groups I and III
metabotropic glutamate receptors also modulate the activity of
NADPH oxidases, the main source of superoxide anions (Mead
et al., 2012).
FUNCTIONS OF GLUTAMATE RECEPTORS IN MICROGLIA
Similar to ATP, glutamate is a chemotactic neurotransmit-
ter for microglia. Microglia stimulated by kainate, via either
AMPA or kainate receptors, undergo dramatic morphological
and cytoskeletal changes characterized by the condensation of
cytoplasmic actin filaments, rapid depolymerization and repoly-
merization, and cytoplasmic redistribution of condensed actin
bundles (Christensen et al., 2006). Actin filament rearrangement
is thought to be involved in locomotion and phagocytosis and to
indicate an increased level of activation. Microglia cells exposed to
glutamate exhibit increased cell membrane ruffling and migrate
to a source of glutamate in cell culture and spinal cord slices. This
chemotaxis is mediated by AMPA and metabotropic glutamate
receptors on the microglia, and is dependent on the redistribu-
tion of actin filaments and tubulin following receptor activation
(Liu et al., 2009).
However, the role of glutamate in regulating baseline motility
remains controversial. Initial studies showed that neuronal neu-
rotransmission and activity-dependent synaptic plasticity does
not affect surveying microglial motility in the hippocampus
(Wu and Zhuo, 2008). However, other studies have suggested
that endogenous glutamatergic neurotransmission positively reg-
ulates the dendriticmorphology and process motility of surveying
microglia (Fontainhas et al., 2011). The processes of surveying
microglia have been demonstrated to make brief (∼5min) and
direct contacts with neuronal synapses at a frequency of approxi-
mately once per hour. These contacts are activity-dependent and
reduce in frequency with reduced neuronal activity (Wake et al.,
2009; Li et al., 2012). Neuronal activity affects the direction but
not the basal level of microglial process motility (Li et al., 2012),
which could explain the previous discrepancy with the article by
Wu and Zhuo. Thus, neuronal activity steers surveying/resting
microglia and facilitates their contacts with highly active neurons.
This effect is not direct, as microglia do not express glutamate
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receptors in processes and lack direct responses to glutamatergic
agonists in situ. Instead, these influences are mediated indirectly
via extracellular ATP, which is released in response to gluta-
matergic neurotransmission through probenecid-sensitive pan-
nexin hemichannels (Fontainhas et al., 2011; Li et al., 2012).
The consequences of these microglia-synapse contacts depend
probably on the nature and intensity of the stimulus. After tran-
sient cerebral ischemia, the duration of these microglia–synapse
contacts is markedly prolonged (∼1 h) and is frequently fol-
lowed by the disappearance of the presynaptic bouton (Wake
et al., 2009). However, an increase in spontaneous neuronal activ-
ity (i.e., by glutamate uncaging or kir channels overexpression
in neurons) leads to the formation of microglial bulbous end-
ings contacts with neurons that, surprisingly, reduce the activity
of contacted neurons. This study suggests a role of surveying
microglial in homeostatic regulation of neuronal activity (Li
et al., 2012). These results suggest that microglia vigilantly mon-
itor and respond to the functional status of synapses either to
eliminate dysfunctional synapses or to silence them. Additional
studies are needed to explore the mechanism and neurotrans-
mitter involved in microglial detection of the functional status of
synapses.
Glutamate is involved in the transmission of the death signal to
microglia. Using the optically transparent larval zebrafish brain,
rapidly propagating Ca2+ waves have been shown to determine
the range of microglial responses to neuronal cell death. Though
Ca2+-mediated microglial responses require ATP, the spreading
of intercellular Ca2+ waves is ATP independent, and glutamate
has been identified as a potent inducer of Ca2+-transmitted
microglial attraction. Thus, the real-time analysis revealed the
existence of a mechanism controlling microglial-targeted migra-
tion to neuronal injuries initiated by glutamate and proceeding
across the brain in the form of a Ca2+ wave (Sieger et al., 2012).
ROLE OF MICROGLIAL NEUROTRANSMITTER RECEPTORS
IN PATHOLOGY
Early during a pathological process, microglia may be stimulated
by either non-self pathogens (stranger signals) or injured-self
components (danger signals). Both stimuli can activate pattern-
recognition receptors, such as the Toll-like receptors, scavenger
receptors, and NOD system. The effector outputs of these stim-
uli focus on the clearance of tissue debris, generation of cues
for tissue restoration, and resistance to pathogens. Together,
these reactions comprise innate immune responses. Subsequent
events may require the establishment of responses, including
lymphocyte effector functions, antibodies, and immunological
memory—collectively termed adaptive immunity. Microglial cells
contribute to this process with antigen presentation, including the
instruction of T cells to adopt varied effector programs (Th1, Th2,
Th17) and, in some cases, directing them to the tissue from which
the pathogenic material originated.
Although the innate immune response is beneficial in prin-
cipal, an excessive and sustained activation of microglial cells
is detrimental to neurons and oligodendrocytes (Merrill et al.,
1993; Bezzi et al., 2001). Microglia activation has been described
extensively in most pathological conditions in the CNS (Block
and Hong, 2005), though its role is still debated (Schwartz et al.,
2006). The outcome of microglial activation is complex and likely
dependent on context. Microglia and macrophages can be acti-
vated by the cytokines interferon-g (IFN-g), IL-17, or LPS to a
pro-inflammatory phenotype (M1), whereas IL-4 or IL-13 induce
a state of alternative activation (M2) that is associated with neu-
roprotective functions that promote repair (Butovsky et al., 2006;
Ponomarev et al., 2007; Kawanokuchi et al., 2008). Understanding
the different processes and regulators of microglial activation will
be important to unraveling their many complex functions. The
thinking behind this dichotomization is that understanding these
two microglial responses may minimize the harmful effects and
capitalize on the beneficial effects (Popovich et al., 2011). In addi-
tion, a given facet of microglial activation that is beneficial in
principle, such as phagocytosis, could turn detrimental under
other circunstances. For example, phagocytosis under inflamma-
tory conditions actively induces neuronal death (Neher et al.,
2011) because inflammation causes viable neurons to express the
“eat-me” signal, phosphatidylserine, on their surface, leading to
their death through phagocytosis.
ROLE OF PURINERGIC RECEPTORS IN CNS INJURY
Purinergic signaling regulates both innate and adaptive immune
responses and is involved in numerous acute insults and chronic
neurodegenerative diseases of the CNS (Burnstock, 2008) because
purine homeostasis is compromised in most diseases. However,
relatively few studies have described the specific contribution of
purinoceptor signaling pathways in microglia to neuropathology.
In this section we summarize the data demonstrating the benefi-
cial role of blocking P2 and P1 receptors, particularly P2X4R and
P2X7R, in different CNS pathologies.
P2 RECEPTORS IN NEUROPATHIC PAIN: P2X4
Spinal microglia react and undergo a series of changes that
directly influence the establishment of neuropathic pain states.
Purinergic signaling via P2X4R is at the center of this reactiv-
ity (Beggs et al., 2012). Microglial P2X4 upregulation determines
the behavioral manifestations of neuropathic pain arising from
peripheral nerve injury and is sufficient to convert the response to
normal non-painful peripheral inputs, from innocuous to noci-
ceptive (review in Beggs et al., 2012). These findings are the basis
for the concept that the microglial phenotype characterized by
dramatic upregulation of P2X4Rs. The P2X4R+ state, is critical
in the etiology of neuropathic pain (Beggs et al., 2012). However,
other microglial purinergic receptors, such as P2X7R, P2Y12R,
and P1 receptors, are also involved in neuropathic pain. The
blockage of P2X7Rs has been shown to alleviate chronic pain in
three different models of neuropathic pain (Honore et al., 2009).
Microglial P2X7Rs might participate in the neuronal hyperex-
citability of dorsal horn neurons and development of neuropathic
pain through the production of pro-inflammatory cytokines and
chemokines (Tsuda et al., 2013). P2X7R also participates in
microglial P2X4R trafficking and assembly (Boumechache et al.,
2009), which could indirectly modulate P2X4R-regulated neuro-
pathic pain. In macrophages and microglia, P2X4 and P2X7 form
homotrimers that interact. P2X7Rs are found predominantly
at the cell surface, whereas P2X4Rs are primarily intracellular.
However, microglial activation induces a rapid translocation of
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P2X4R to the surface, which is an efficient means of enhancing
the function of P2X4R (Boumechache et al., 2009).
P2Y12R expression levels are also dramatically increased
in microglial cells in the spinal cord after peripheral nerve
injury, and the blockage of P2Y12Rs alleviates neuropathic pain
(Kobayashi et al., 2008; Tozaki-Saitoh et al., 2008). After nerve
injury, microglia are more abundant in layers II-III of the dor-
sal horn than in other areas, and some of them adhere to
and engulf both injured and uninjured myelinated axons. This
microglial engulfment is controlled by P2Y12R activation and
directly involved in tactile allodynia (Maeda et al., 2010). The
upregulation of other metabotropic P2 receptors, such as P2Y6R,
P2Y13R, and P2Y14R, after nerve injury was reported recently
(Kobayashi et al., 2012), and the concomitant block of the three
receptors results in a longer suppressive effect on pain behavior
(Kobayashi et al., 2012). In view of the crucial role played by dif-
ferent purinergic receptors in neuropathic pain, investigating the
mechanisms of ATP release and how to modulate it as a means of
attenuating neuropathic pain will be important.
Interestingly, a recent paper describes the involvement of
microglial P2X4Rs in hyperalgesia produced by the gold-standard
opiate analgesics. Morphine and other opiates are indispensable
in the treatment of moderate-to-severe postoperative and chronic
pain, but the use of these drugs is plagued by the development
of two major problems: hyperalgesia and tolerance. Hyperalgesia
is a sensitization process in which opioids, paradoxically, cause
pain hypersensitivity. The spinal dorsal horn lamina I neurons
are central targets for the analgesic effects of morphine and other
opiates, and mediate morphine-induced hyperalgesia and toler-
ance. In particular, morphine induces analgesia via inhibition
in lamina I neurons. In contrast, morphine induces hyperalge-
sia via the P2X4R-BDNF-KCC2 disinhibition cascade between
microglia and lamina I neurons. Thus, BDNF release by activation
of P2X4Rs inmicroglia impairs Cl− homeostasis by downregulat-
ing K+–Cl− co-transporter KCC2 in those neurons (Ferrini et al.,
2013).
P2X4Rs are also involved in other acute insults. Thus, the
activation of microglia after hypoxia in the neonatal rat brain,
a model of periventricular white matter damage, is mediated
by P2X4R signaling (Li et al., 2011). P2X4 is also upregu-
lated in microglial cells in the CA1 and transition zone to CA2
regions of the hippocampus after ischemia (Cavaliere et al., 2003),
and its blockade confers neuronal protection (Cavaliere et al.,
2005). Conversely, activation of P2X4 purinergic signaling in
glia after traumatic injury stimulates the synthesis and release of
thrombospondin-1, an extracellular matrix molecule that induces
synapse formation during development, and it may play a role in
CNS repair and remodeling after injury (Tran and Neary, 2006).
P2X7 RECEPTORS: A PROMISING TARGET FOR NEUROPROTECTION
In immune cells, P2X7R activation promotes assembly of the
inflammasome, and caspase-1-dependent cleavage and release of
biologically active IL-1β and IL-18 in vitro and in vivo, ulti-
mately leading to a rapid form of cell death called pyroptosis
(Miao et al., 2011). P2X7R antagonists improve neuronal viability
by inhibiting P2X7R-activated NLRP3 inflammasome formation
and the subsequent IL-1β release from glia (Murphy et al., 2012).
P2X7R stimulation in neurons also induces inflammasome acti-
vation in these cells (Silverman et al., 2009). In addition, P2X7R
activation in neurons and oligodendrocytes leads to a massive
calcium influx that induces mitochondrial damage and initi-
ates the apoptotic cascade (Matute et al., 2007; Díaz-Hernández
et al., 2009; Arbeloa et al., 2012). P2X7Rs have unique properties
that could be relevant to pathological conditions. First, P2X7Rs
have high Ca2+ permeability, similar to that of NMDA receptors.
Second, in contrast to NMDA receptors, P2X7Rs can be activated
at resting membrane potentials and do not require membrane
depolarization. Finally, P2X7Rs do not desensitize and open a
large pore that causes cytolytic cell death after prolonged activa-
tion (Surprenant et al., 1996). Prolonged activation of P2X7Rs
kills all CNS cells, including neurons (Jun et al., 2007; Díaz-
Hernández et al., 2009; Arbeloa et al., 2012), oligodendrocytes
(Matute et al., 2007), astrocytes (Kim et al., 2011), and microglia
(Harada et al., 2011).
Acute insults, such as trauma and ischemia, lead to a massive
release of nucleotides from disrupted cells at a level sufficient to
activate low-affinity P2X7Rs in neighboring neurons and oligo-
dendrocytes, leading to their death by excitotoxicity (Wang et al.,
2004; Domercq et al., 2010; Arbeloa et al., 2012). Both insults
induced the activation of microglia and dramatic remodeling
of purinoceptors in microglia, which could influence microglial
functions with beneficial or detrimental consequences. P2X7R
antagonists modulate microglial activation and the inflammatory
response after ischemia, which could contribute to the therapeutic
value of these antagonists (Melani et al., 2006; Chu et al., 2012).
Cerebral microvascular occlusion elicits microvascular injury,
mimicking the different degrees of stroke severity observed in
patients. Recently, a role of microglial P2X7R in this type of injury
has been proposed. After inducing focal microsphere embolism to
microvessels, microglia are recruited to the lesion site through a
P2X7R-dependent mechanism and release FasL contributing to
neuroinflammation (Lu et al., 2012). The microglial response to
P2X7R activation appears to be region specific. Thus, in the status
epilepticus (SE), microglia appear amoeboid or phagocytic in the
dentate gyrus (DG) and piriform cortex due to P2X7R activation,
but elongated in the CA1 hippocampal regions and frontoparietal
cortex (Choi et al., 2012).
P2X7R antagonists have also been protective in animal mod-
els of MS, amyotrophic lateral sclerosis, Parkinson’s disease,
Huntington’s disease, and Alzheimer’s disease (Table 2). Whether
protection is mediated by blocking neuronal or oligodendroglial
excitotoxicity, inflammation, or both remains to be determined in
most neurodegenerative diseases. In Alzheimer’s disease, different
mechanisms determine the beneficial effects of P2X7R antago-
nists. In vivo administration of P2X7R antagonists reduce amyloid
plaque formation through a signaling cascade involving the acti-
vation of GSK-3 kinase and increased non-amyloidogenic amy-
loid precursor protein processing by α-secretase (Diaz-Hernandez
et al., 2012). However, P2X7Rs are necessary for β-amyloid-
induced microglial activation (Sanz et al., 2009). The treat-
ment of chronic EAE, the animal model of MS, with P2X7R
antagonists reduces demyelination and ameliorates associated
neurological symptoms (Matute et al., 2007). Because ATP sig-
naling can trigger oligodendrocyte excitotoxicity (Matute et al.,
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2007), the beneficial effect of P2X7R antagonists in this pathol-
ogy may be due its protective role in oligodendrocytes and
axons, more than the possible interference of the immune sys-
tem. Importantly, sustained activation of P2X7Rs in vivo causes
lesions that are reminiscent of the major features of MS plaques,
and P2X7 RNA and protein levels are elevated in normal-
appearing axon tracts in MS patients, suggesting that oligoden-
droglial signaling through P2X7Rs is enhanced in MS, which
may render this cell type more vulnerable to ATP dysregulation
(Matute et al., 2007).
P2X7Rs have a low affinity for ATP (100μM-10mM), and
ATP levels in the extracellular space are in the low nanomolar
range due to its rapid inactivation by powerful ubiquitous ecto-
ATPases, whether this receptor is activated under physiological
conditions is unclear. However, ATP is available at high concen-
trations within the cytoplasm (1–3mM) and quickly released in
sufficient quantities to activate P2X7Rs following cell damage
in acute insults and chronic neurodegenerative diseases. These
characteristics indicate an almost exclusive activation of P2X7Rs
in pathological states and a low or negligible interference with
Table 2 | Neuroprotective properties of P2X7 receptor antagonists.
Disease P2X7 receptor involvement References
CHRONIC NEURODEGENERATION
Alzheimer’s disease P2X7 mediates microglial neuroinflammatory reaction in different
models of Alzheimer’s disease
Parvathenani et al., 2003; Rampe et al., 2004;
McLarnon et al., 2006
P2X7 receptor blocks α-secretase activity/P2X7 triggers α-secretase
activity
Delarasse et al., 2011; León-Otegui et al., 2011
In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s
disease
Diaz-Hernandez et al., 2012
Upregulation of P2X7 in microglia in the cerebral cortex of the
APPswe/PS1dE9 mice, a mouse model of AD
Lee et al., 2011
Amyotrophic lateral
sclerosis
P2X7 receptor activation in spinal cord SOD1(G93A) astrocytes
leads to motor neuron death
Gandelman et al., 2010
P2X7 is overexpressed in activated microglial in ALS Yiangou et al., 2006
Parkinson’s disease ATP mediates necrotic cell death in SN4741 dopaminergic neurons
though P2X7 receptors
Jun et al., 2007
P2X7 increases in astrocytes in the rotenone Parkinson’s disease
model
Gao et al., 2011
Huntington’s disease P2X7 antagonists prevented neuronal apoptosis in HD mice Díaz-Hernández et al., 2009
Multiple sclerosis P2X7−/− mice are more susceptble to EAE, the MS model Chen and Brosnan, 2006; Witting et al., 2006
P2X7 mediates ATP excitotoxicity to oligodendrocytes and P2X7
blockage improves neurological damage in EAE
Matute et al., 2007
Association of gain of function P2X7 variants with MS Oyanguren-Desez et al., 2011
ACUTE INSULTS
Epilepsy Enhanced purinergic signaling in microglia in status epilepticus Avignone et al., 2008
P2X7−/−mice and Panx1 gene silencing showed greater
susceptibility to pilocarpine-induced seizures
Kim and Kang, 2011
P2X7 antagonists as well Panx1 gene silencing blocked status
epilepticus induced by kainic acid
Santiago et al., 2011; Engel et al., 2012
P2X7 antagonists prevented astroglial apoptosis in status epilepticus Kim et al., 2009
Ischemia P2X7 receptors is overexpressed in activated microglia and in
neurons in different models of in vitro and in vivo ischemia
Cavaliere et al., 2004, 2005; Franke et al., 2004
P2X7 antagonists reduces neuronal damage and infarct size after
transient focal ischemia
Le Feuvre et al., 2003; Melani et al., 2006;
Arbeloa et al., 2012
P2X7 blockage amielorates oligodendroglial and axonal damage after
white matter ischemia
Domercq et al., 2010
Trauma P2X7 receptor inhibition improves recovery after spinal cord injury Wang et al., 2004; Peng et al., 2009
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normal brain functionality. Therefore, P2X7R could be an ideal
therapeutic target for neurodegenerative diseases.
ADENOSINE RECEPTORS
Adenosine plays a relevant role as a neuromodulator and, thus,
contributes to MS, a chronic disease with an autoimmune and
inflammatory basis. A1 receptor-null mice have been shown to
develop more severe demyelination and motor symptoms in
chronic EAE compared to their wild-type counterparts (Tsutsui
et al., 2004). The aggravation of EAE is mostly mediated by cells
in themicroglial lineage and involves the release of toxic factors by
macrophages/microglia lacking A1 receptors (Tsutsui et al., 2004).
More recently, a protective role of adenosine A2A receptors was
reported in this model. Genetic inactivation of the A2A recep-
tor exacerbates EAE pathology in mice. In addition, A2A receptor
knockout mice display increased inflammatory cell infiltration
and enhanced microglial cell activation in the cortex, brainstem,
and spinal cord (Mills et al., 2012; Yao et al., 2012).
Inflammation also contributes to post-ischemic delayed cere-
bral damage. A3 adenosine receptor expression is modulated by
the activation state of inflammatory cells and, in turn, its acti-
vation regulates the inflammatory activity of immune cells (Bar-
Yehuda et al., 2007; Ochaion et al., 2009). The administration of
A3 agonists before or immediately after ischemic insults has been
shown to significantly protect the brain in rodent ischemia mod-
els (Von Lubitz et al., 1994, 2001; Chen et al., 2006). Importantly,
A3 agonists protect against ischemic brain injury when applied 7 h
after the ischemic insult (5.5 h after starting reperfusion) (Choi
et al., 2011). The effect could be due to an inhibitory effect of
the A3 agonist on microglial/monocyte migration through the
regulation of Rho GTPases (Choi et al., 2011).
ROLE OF GLUTAMATE RECEPTORS IN CNS INJURY
The possible contribution of microglia glutamate signaling to
pathology has not been analyzed thoroughly. Few studies have
demonstrated that the activation of ionotropic glutamate recep-
tors in microglia has deleterious consequences to neurons and
oligodendrocytes. NMDA receptor expression is upregulated in
activated microglia following ischemia (Gottlieb and Matute,
1997; Kaur et al., 2006), which contributes to oligodendrocyte
damage in hypoxic postnatal rats, a model of periventricular
white matter damage. The activation of NMDA receptors in
microglia leads to NO release in response to NF-kb signaling,
which is known to induce oligodendrocyte cell death (Li et al.,
2005). Pharmacological inhibition of NMDA receptors (MK801),
NF-kb (BAY), and iNOS (1400w) prevents oligodendrocyte cell
death (Murugan et al., 2011). Thus, NMDA receptor block-
ade protects oligodendrocytes by reducing the release of NO
from microglia (Tahraoui et al., 2001; Murugan et al., 2011),
in addition to the effect of direct blockage of NMDA recep-
tors in these cells (Manning et al., 2008). In contrast, kainate-
activated microglia induce IL-1β and TNF-α release, which medi-
ate increased excitability of hippocampal CA3 neurons (Zheng
et al., 2010; Zhu et al., 2010), an effect that could be relevant in
acute insults.
The activation of microglial metabotropic receptors has
been reported to regulate superoxide production by modulating
NADPH oxidase (Nox) activity. Nox enzymes are major gener-
ators of ROS, which contribute to the progression of CNS dis-
orders as diverse as amyotrophic lateral sclerosis, schizophrenia,
Alzheimer’s disease, Parkinson’s disease, and stroke. Microglia
are the predominant cells expressing Nox enzymes (Harrigan
et al., 2008). Nox activation is elicited by agonists of metabotropic
mGlu3 receptors, promotes neurotoxicity, and is inhibited by
antagonists of mGluR5 receptors (Mead et al., 2012). For exam-
ple, the regulation of Nox activity by mGluRs could con-
tribute to limiting microglial activation after traumatic brain
injury, improving motor and cognitive recovery (Byrnes et al.,
2012).
ROLE OF MICROGLIA IN GLUTAMATE AND ATP
HOMEOSTASIS AND ITS CONTRIBUTION TO
NEURODEGENERATIVE DISEASES
ATP HOMEOSTASIS
ATP homeostasis is compromised in most CNS pathologies.
Immediately after acute CNS injury, astrocytes and damaged cells
release ATP, resulting in rapid activation of microglia. ATP and
UTP are released by apoptotic cells as a “find-me” signal in
the earliest stages of death to recruit phagocytes to the plasma
membrane channel pannexin 1 (PANX1). Pharmacological inhi-
bition and siRNA-mediated knockdown of PANX1 leads to
decreased nucleotide release and monocyte recruitment by apop-
totic cells (Chekeni et al., 2010). Pannexins also open following
ischemic insult (Thompson et al., 2006; Domercq et al., 2010;
MacVicar and Thompson, 2010), in response to high extracellu-
lar K+ (Silverman et al., 2009), after NMDA receptor stimulation
(Thompson et al., 2008), and, surprisingly, in response to caspase
cleavage (Chekeni et al., 2010), which suggests that pannexins
may open in most pathological contexts. However, the expression
of pannexins in microglia and their possible influence on ATP
release under normal conditions and after microglial activation
has not been characterized. Finally, microglia are able to release
ATP after activation with LPS, leading to an increase in excitatory
neurotransmission (Pascual et al., 2012). Different mechanisms
have been proposed, including microglial release of ATP via zinc
uptake by zinc transporters (Higashi et al., 2011). In addition,
lysosomes in microglia contain abundant ATP and exhibit Ca2+-
dependent exocytosis in response to various stimuli (Dou et al.,
2012).
GLUTAMATE HOMEOSTASIS
Since the discovery of excitotoxicity and its contribution to neu-
ronal cell death in neuropathology, numerous studies have aimed
to understand the origin of alterations in glutamate homeosta-
sis, which determines lethal overactivation of glutamate receptors.
In vitro studies have demonstrated that activated microglia play a
deleterious role by releasing glutamate or altering its homeostasis.
Surprisingly, a recent study demonstrated a neuroprotective role
of surveying microglia in excitotoxicity-induced neurodegenera-
tion in the hippocampus (Vinet et al., 2012). This region exhibits
differential sensitivity to excitotoxicity, with the CA1 region more
vulnerable than CA3 or DG neurons. However, ablation of ram-
ified microglia in the latter two areas exacerbates neuronal cell
death, suggesting a protective role of surveying microglia in these
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areas (Vinet et al., 2012). The mechanism by which surveying
microglia confer protection remains to be determined.
Microglia, mainly in the activated state, contribute to alter-
ations in neurotransmitter homeostasis via three main mech-
anisms: (1) release of excitotoxins, including glutamate (Piani
et al., 1992), quinolinate (Heyes et al., 1996), D-serine (Wu et al.,
2004), and ATP; (2) interfering with glutamate uptake, which
is mainly carried out by astrocytes, leading to extracellular glu-
tamate accumulation; or (3) altering astrocyte gliotransmitter
release (including glutamate) or synaptic transmission.
A key determinant of microglial neurotoxicity is the release
of excitotoxins, such as glutamate. The vast majority of glu-
tamate exported from activated microglia can be attributed
to the x−c exchange mechanism (a.k.a., SLC7A11 or CCBR1).
This antiporter is a membrane-bound, Cl−-dependent, Na+-
independent antiporter that mediates the cellular uptake of cys-
tine in exchange for glutamate at a 1:1 ratio, primarily following
the relative concentration gradients of each of these amino acids
(Bridges et al., 2012). This mechanism becomes extremely active
in microglia because it is the primary route for internalizing
cystine, which is converted to cysteine intracellularly, the rate-
limiting substrate in glutathione synthesis (Bridges et al., 2012).
As activated microglia produce ROS, they place themselves under
severe oxidative stress. Although the bulk of superoxide produced
by Nox is released from microglia, some remains intracellu-
lar. Thus, the microglial oxidative burst creates a GSH shortage
that is alleviated by cystine influx through the x−c antiporter,
extruding glutamate in the balance (Barger et al., 2007). The
obligate exchange of glutamate could be deleterious to neuronal
cells and other tissues that are susceptible to excitotoxic damage.
Accordingly, the cystine/glutamate exchanger has been implicated
in glutamate-associated disorders, such as glioma-derived epilep-
tic seizures (Buckingham et al., 2011), oxidative glutamate toxi-
city (Oka et al., 1993; Albrecht et al., 2010), Alzheimer’s disease
(Barger and Basile, 2001; Qin et al., 2006), bacterial infection/LPS
(Taguchi et al., 2007), MS (Domercq et al., 2007; Pampliega
et al., 2011), Parkinson’s disease, AIDS (Zeng et al., 2010), virally-
induced encephalopathy (Espey et al., 1998; Qin et al., 2010),
tumor proliferation (Ogunrinu and Sontheimer, 2010), antigen
presentation (D’Angelo et al., 2010), and hypoxia (Fogal et al.,
2007; Jackman et al., 2010).
Both surveying and activated microglia release glutamate
through the cystine/glutamate antiporter (Domercq et al., 2007)
(Figure 2). However, glutamate released through surveying
microglia is rapidly and efficiently removed by glutamate trans-
porters in other glial cells, mainly astrocytes, though also oligo-
dendrocytes (Domercq et al., 1999). In contrast, the activation
of microglia induces the release of factors, such as ROS, TNF-
α, and IL-1β, that impair the function of EAATs, resulting in an
increase in the extracellular levels of glutamate (Domercq et al.,
2007). In addition, autoantigen-activated myelin basic protein-
specific T cells also inhibit EAATs (Korn et al., 2005), suggesting
that these mechanisms could contribute to alterations in gluta-
mate homeostasis in the plasma and cerebrospinal fluid of MS
patients. Gliomas also achieve excitotoxic levels of glutamate
through high levels of system x−c activity coupled with a relative
absence of sodium-dependent transport (Ye and Sontheimer,
FIGURE 2 | Activated microglia can kill oligodendrocytes via a dual
mechanism leading to glutamate excitotoxicity. Microglia release
glutamate, primarily through the cystine/glutamate exchange system
(system x−c ), which is highly active in these cells due to its high rate of
reactive oxygen species (ROS) production. Thus, cystine is intracellularly
converted into cysteine, the rate-limiting substrate in glutathione synthesis.
Under physiological conditions, glutamate released by the exchanger is
efficiently taken up by glutamate transporters expressed in surrounding
cells, including astrocytes and oligodendrocytes. In contrast, microglia
activated by pro-inflammatory stimuli (e.g., LPS acting at TLR4) release
ROS and pro-inflammatory cytokines that impair the function of glutamate
transporters, such as TNF-α and IL-1β, elevating extracellular glutamate
levels. In addition, the over-expression of system x−c in activated microglia
increases ambient glutamate concentrations. Together, these deleterious
effects on glutamate homeostasis can result in excitotoxicity (Domercq
et al., 2007). CySS, cystine; Glu, glutamate; LPS, lipopolysaccharide; TLR4,
Toll-like receptor.
1999; Ye et al., 1999; Kim et al., 2001; Takano et al., 2001;
Rothstein, 2002; Chung et al., 2005). Glutamate released by sys-
tem x−c in gliomas triggers excitotoxic cell death in the regions
surrounding the tumor, allowing the tumor cells to migrate and
invade (Lyons et al., 2007). Interestingly, glutamate export by the
microglial cystine/glutamate antiporter is inhibited by mGluRII
and III metabotropic glutamate receptor activation (McMullan
et al., 2012).
Finally, microglia may regulate astrocyte-dependent synaptic
modulation, called gliotransmission (Perea et al., 2009; Pascual
et al., 2012). The first evidence of gliotransmission came from the
seminal observation that glutamate release from cultured astro-
cytes (in this case stimulated via CXCR4 chemokine receptors) is
dramatically amplified by the presence of activated microglia in
the astrocytic microenvironment (Bezzi et al., 2001). Constitutive
TNFα was reported to control astrocyte gliotransmission under
physiological conditions (Stellwagen and Malenka, 2006; Santello
et al., 2011). However, microglia activated by LPS release mas-
sive concentrations of TNF-α (approximately 10-fold); at these
high concentrations, TNF-α changes its mode of action, not only
gating, but also directly causing glutamate release from astro-
cytes. This alternative TNF-α action is mediated by prostaglandin
E2 (PGE2) and was found to induce slow excitotoxic neu-
ronal damage, both in cell culture and in vivo (Bezzi et al.,
2001).
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CONCLUSIONS
Neurotransmitter signaling is relevant to microglial functions.
Microglia express receptors for neurotransmitters and con-
tribute to neurotransmitter homeostasis. In particular, microglia
are endowed with virtually all types of purinergic receptors
that are differentially expressed at different stages and medi-
ate process extension and retraction, cytokine release, migra-
tion, proliferation, and phagocytosis. In turn, activated microglia
can release ATP and modulate synaptic activity. In addition,
microglia also have an ample variety of glutamate receptors
that mediate chemotaxis, ATP release, and surveillance of the
functional status of synapses. Notably, microglia are critical
controllers of glutamate homeostasis via the cystine/glutamate
Xc- exchanger. Both ATP and glutamate receptors in microglia
are relevant to neuroinflammation in various pathological con-
ditions, including neurodegenerative diseases, and can be valu-
able targets for drug development in neuropathic pain and
neuroprotection.
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